Literature DB >> 11388415

Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes.

D Hernandez1, K Sugaya, T Qu, E McGowan, K Duff, M McKinney.   

Abstract

The basalo-cortical cholinergic system was characterized in mice expressing mutant human genes for presenilin-1 (PS1), amyloid precursor protein (APP), and combined PS/APP. Dual immunocytochemistry for ChAT and A beta revealed swollen cholinergic processes within cortical plaques in both APP and PS/APP brains by 12 months, suggesting aberrant sprouting or redistribution of cholinergic processes in response to amyloid deposition. At 8 months, cortical and subcortical ChAT activity was normal (PS/APP) or elevated (PS, APP frontal cortex), while cholinergic cell counts (nBM/SI) and receptor binding were unchanged. ChAT mRNA was up-regulated in the nBM/SI of all three transgenic lines at 8 months. The data indicate that the basal forebrain cholinergic system does not degenerate in mice expressing AD-related transgenes, even in mice with extreme amyloid load. The

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11388415     DOI: 10.1097/00001756-200105250-00018

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  14 in total

1.  Amyloid precursor protein-induced axonopathies are independent of amyloid-beta peptides.

Authors:  Gorazd B Stokin; Angels Almenar-Queralt; Shermali Gunawardena; Elizabeth M Rodrigues; Tomás Falzone; Jungsu Kim; Concepción Lillo; Stephanie L Mount; Elizabeth A Roberts; Eileen McGowan; David S Williams; Lawrence S B Goldstein
Journal:  Hum Mol Genet       Date:  2008-08-11       Impact factor: 6.150

Review 2.  Beta-amyloid and cholinergic neurons.

Authors:  Vladimír Dolezal; Jana Kasparová
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

Review 3.  Basal forebrain cholinergic dysfunction in Alzheimer's disease--interrelationship with beta-amyloid, inflammation and neurotrophin signaling.

Authors:  Reinhard Schliebs
Journal:  Neurochem Res       Date:  2005 Jun-Jul       Impact factor: 3.996

4.  Reduction in CHT1-mediated choline uptake in primary neurons from presenilin-1 M146V mutant knock-in mice.

Authors:  Daniel J Payette; Jun Xie; Qing Guo
Journal:  Brain Res       Date:  2006-12-29       Impact factor: 3.252

5.  Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease.

Authors:  Pamela E Potter; Paula K Rauschkolb; Yoga Pandya; Lucia I Sue; Marwan N Sabbagh; Douglas G Walker; Thomas G Beach
Journal:  Acta Neuropathol       Date:  2011-05-01       Impact factor: 17.088

6.  Cholinotrophic basal forebrain system alterations in 3xTg-AD transgenic mice.

Authors:  Sylvia E Perez; Bin He; Nadeem Muhammad; Kwang-Jin Oh; Margaret Fahnestock; Milos D Ikonomovic; Elliott J Mufson
Journal:  Neurobiol Dis       Date:  2010-10-16       Impact factor: 5.996

7.  Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis.

Authors:  Sonia Boncristiano; Michael E Calhoun; Peter H Kelly; Michelle Pfeifer; Luca Bondolfi; Martina Stalder; Amie L Phinney; Dorothee Abramowski; Christine Sturchler-Pierrat; Albert Enz; Bernd Sommer; Matthias Staufenbiel; Mathias Jucker
Journal:  J Neurosci       Date:  2002-04-15       Impact factor: 6.167

8.  Presenilin-1 mutation impairs cholinergic modulation of synaptic plasticity and suppresses NMDA currents in hippocampus slices.

Authors:  Yue Wang; Nigel H Greig; Qian-sheng Yu; Mark P Mattson
Journal:  Neurobiol Aging       Date:  2008-02-20       Impact factor: 4.673

9.  Cholinergic forebrain degeneration in the APPswe/PS1DeltaE9 transgenic mouse.

Authors:  Sylvia E Perez; Saleem Dar; Milos D Ikonomovic; Steven T DeKosky; Elliott J Mufson
Journal:  Neurobiol Dis       Date:  2007-06-27       Impact factor: 5.996

Review 10.  The place of choline acetyltransferase activity measurement in the "cholinergic hypothesis" of neurodegenerative diseases.

Authors:  Antonio Contestabile; Elisabetta Ciani; Andrea Contestabile
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.